natgillin/translations-raw huggingface dataset:
After combined administration of enoxaparin (40 mg single dose) with rivaroxaban (10 mg single dose) an additive effect on anti-factor Xa activity was observed without any additional effects on clotting tests (PT, aPTT).
Pri sočasni uporabi odmerkov enoksaparina (40 mg na posamezni odmerek) in rivaroksabana (10 mg na posamezni odmerek) so opazili aditivno zaviranje faktorja Xa, brez dodatnega učinka na teste strjevanja krvi (PČ, aPTČ).
After completing each 28 day cycle, you should start a new ‘cycle’ over the next 28 days.
Po dokončanju vsakega 28-dnevnega cikla boste začeli nov ‘cikel’, ki bo trajal naslednjih 28 dni.
After completing each cycle, start a new one.
Po končanju vsakega cikla začnite z novim.
After completing the injection and removing the needle, you should fold over the needle protector and snap it over the needle.
Po koncu injiciranja in odstranitvi igle prepognite ščitnik igle in ga poveznite prek igle.
After completing the injection, place a cotton ball or gauze pad on the skin over the injection site.
Po zaključenem injiciranju položite na mesto injiciranja blazinico iz vate ali zloženec iz gaze.
After completion of a four dose primary course (i.e at month 7), 90.9% of Fendrix recipients were seroprotected ( 10 mIU/ml) against hepatitis B, in comparison with 84.4% in a control group who received the commercially available hepatitis B vaccine.
Po zaključenem osnovnem cepljenju s štirimi odmerki cepiva (npr. v 7. mesecu) je bilo 90,9 % oseb, ki so bile cepljene s cepivom Fendrix serozaščitenih (10 i.e/l) pred okužbo z virusom hepatitisa B v primerjavi s 84,4 % oseb v kontrolni skupini, ki so bile cepljene s komercialno dostopnim cepivom proti hepatitisu B.
After completion of six cycles of carboplatin-paclitaxel chemotherapy or upon premature discontinuation of chemotherapy, patients on the Avastin + carboplatin–paclitaxel arm continued to receive Avastin as a single agent every 3 weeks until disease progression.
Po zaključku 6 ciklov kemoterapije s karboplatinom in paklitakselom ali po predčasnem zaključku kemoterapije so bolniki v skupini, ki je prejemala zdravilo Avastin s karboplatinom in paklitakselom, do napredovanja bolezni prejemali samo zdravilo Avastin vsake 3 tedne.
After concomitant administration of lixisenatide 20 mcg and ramipril 5 mg during 6 days, the AUC of ramipril was increased by 21% while the Cmax was decreased by 63%.The AUC and Cmax of the active metabolite (ramiprilat) were not affected.
Po sočasni 6-dnevni uporabi 20 mcg liksisenatida in 5 mg ramiprila se je AUC ramiprila povečala za 21 %, njegova Cmax pa se je znižala za 63 %.
After considering all of the available data on the effects of the medicine, the Committee decided that Daliresp’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor je ob upoštevanju vseh razpoložljivih podatkov o učinkih zdravila zaključil, da so koristi zdravila Daliresp večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
After considering all of the available data on the effects of the medicine, the Committee decided that Daxas’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor je ob upoštevanju vseh razpoložljivih podatkov o učinkih zdravila zaključil, da so koristi zdravila Daxas večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
After considering all of the available data on the effects of the medicine, the Committee decided that Libertek’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor je ob upoštevanju vseh razpoložljivih podatkov o učinkih zdravila zaključil, da so koristi zdravila Libertek večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
After correcting for body weight, male patients had a larger Vc (+ 20%) than female patients.
Po prilagoditvi glede na telesno maso so imeli bolniki večji volumen osrednjega prostora (+20 %) kot bolnice.
After correcting for the BSA effect, other demographics such as age, body weight and sex did not have clinically significant effects on bortezomib clearance.
Po prilagoditvi glede na BSA drugi demografski dejavniki kot so starost, telesna masa in spol, niso imeli klinično pomembnega vpliva na očistek bortezomiba.
After Cycle 1, the drug could be delivered as a 1-hour infusion.
Po prvem ciklusu se lahko zdravilo daje kot 1-urna infuzija.
After day 16, abnormal clinical signs in addition to those clinical signs listed above and occurring in greater than 1% of the dogs receiving oclacitinib included pyoderma, non-specified dermal lumps, otitis, histiocytoma, cystitis, yeast skin infections, pododermatitis, lipoma, enlarged lymph nodes (lymphadenopathy), nausea, increased appetite and aggression.
Po dnevu 16 so se poleg kliničnih znakov, ki so navedeni zgoraj in so jih opazili pri več kot 1 % psov, ki so prejemali oklacitinib, pojavili tudi: pioderma, nespecifični kožni vozliči, otitis, histiocitom, okužbe kože s kvasovkami, pododermatitis, lipom, limfadenopatija, nauzea, povečan apetit in agresija.
After day 16, abnormal clinical signs, in addition to those clinical signs listed above and occurring in greater than 1% of the dogs receiving oclacitinib included pyoderma, non-specified dermal lumps, otitis, histiocytoma, cystitis, yeast skin infections, pododermatitis, lipoma, lymphadenopathy, nausea, increased appetite and aggression.
Po dnevu 16 so se poleg kliničnih znakov, ki so navedeni zgoraj in so jih opazili pri več kot 1 % psov, ki so prejemali oklacitinib, pojavili tudi: pioderma, nespecifični kožni vozliči, otitis, histiocitom, okužbe kože s kvasovkami, pododermatitis, lipom, limfadenopatija, nauzea, povečan apetit in agresija.
After delivery, insulin requirements return rapidly to pre-pregnancy values.
Po porodu se potreba po insulinu hitro vrne na vrednosti pred nosecnostjo.
after diluting to concentrations as low as 1 mg/mL.
po redčenju do najmanjše koncentracije 1 mg/ml.
after diluting to concentrations as low as 1 mg/mL.
po redčenju do najnižje koncentracije 1 mg/ml.
after diluting to up to 5 times the original volume of concentrate (up to 4 parts of diluent to 1 part of concentrate).
po redčenju do največ 5-kratnega začetnega volumna koncentrata (do 4 deli raztopine za redčenje na 1 del koncentrata).
After dilution
Po redčenju
After dilution
Po redčenju:
After dilution (mixing of 5 ml of the reconstituted solution into an infusion bag [total volume of 50 ml] of glucose solution or sodium chloride solution) 1 ml contains 5 mg bivalirudin.
Po nadalnjem redčenju (5 ml rekonstituirane raztopine se v infuzijski vrečki [skupni volumen 50 ml] zmeša z raztopino glukoze ali natrijevega klorida)1 ml vsebuje 5 mg bivalirudina.
After dilution 1 mL contains 200 micrograms cangrelor
Po redčenju 1 ml vsebuje 200 mikrogramov kangrelorja.
After dilution 1 ml contains 5 mg bivalirudin.
Po redčenju 1 ml vsebuje 5 mg bivalirudina.
After dilution 1 mL of solution contains 200 micrograms cangrelor.
Po redčenju 1 ml raztopine vsebuje 200 mikrogramov kangrelorja.
After dilution 1ml contains 5 mg bivalirudin
Po razredčitvi 1 ml vsebuje 5 mg bivalirudina
After dilution 1ml contains 5 mg bivalirudin.
Po razredčitvi 1 ml vsebuje 5 mg bivalirudina.
After dilution in intravenous solutions, TRISENOX is chemically and physically stable for 24 hours at 15-30°C and 48 hours at refrigerated (2-8°C) temperatures.
Po redčenju v intravenskih raztopinah je zdravilo TRISENOX kemijsko in fizikalno stabilno 24 ur pri temperaturi med 15 in 30 °C in 48 ur pri nižjih temperaturah (2–8 °C).
After dilution in sodium chloride 9 mg/mL (0.9 %) solution for injection, olaratumab is administered as an intravenous infusion over approximately 60 minutes.
Po redčenju v 9 mg/ml (0,9-odstotni) raztopini natrijevega klorida za injiciranje se olaratumab aplicira v obliki približno 60 minut trajajoče intravenske infuzije.
After dilution in the dosing cups the preparation should be used within 24 hours.
Po redčenju v odmernih mericah je treba zdravilo porabiti v 24 urah.
After dilution in the dosing cups, the preparation should be used within 24 hours.
Po razredčenju v odmernih mericah morate pripravek porabiti v 24 urah.
After dilution proceed to the step ‘Injecting the solution’.
Po razredčenju nadaljujte s korakom "Injiciranje raztopine".
After dilution the infusion is stable for 24 hours at 2 °C - 8 °C (in a refrigerator)
Po razredčitvi je infuzijska raztopina stabilna 24 ur pri 2 ° C - 8 ° C (v hladilniku).
After dilution the infusion solution is stable for 24 hours at 2 °C - 8 °C (in a refrigerator)
Po razredčitvi je infuzijska raztopina stabilna 24 ur pri temperaturi med 2 C in 8 C (v hladilniku)
After dilution the infusion solution is stable for 24 hours at 2-8 °C (in a refrigerator)
Po razredčitvi je infuzijska raztopina stabilna 24 ur pri temperaturi med 2 C in 8°C (v hladilniku).
After dilution the infusion solution is stable for 24 hours at 2-8 °C (in a refrigerator)
Po razredčitvi je infuzijska raztopina stabilna 24 ur pri temperaturi med 2 °C in 8 °C (v hladilniku).
After dilution the infusion solution is stable for 24 hours at 2-8 °C (in a refrigerator).
Po razredčitvi je infuzijska raztopina stabilna 24 ur pri temperaturi med 2 C in 8 C (v hladilniku).
After dilution the infusion solution is stable for 24 hours at 2-8°C (in a refrigerator)
Po razredčitvi je infuzijska raztopina stabilna 24 ur pri temperaturi med 2 °C in 8 °C (v hladilniku).
After dilution the product is stable for 24 hours when stored at 2°C -8°C and for 4 hours when stored at 25°C. From a microbiological point of view, the product should be used immediately.
Po redčenju je zdravilo stabilno 24 ur, če je shranjeno pri temperaturi 2 °C–8 °C, in 4 ure, če je bila hranjena pri 25 °C. Z mikrobiološkega stališča je treba zdravilo uporabiti takoj.
After dilution the product is stable for 24 hours when stored at 2°C -8°C and for 4 hours when stored at 25°C. From a microbiological point of view, the product should be used immediately.
Po redčenju je zdravilo stabilno 24 ur, če je shranjeno pri temperaturi 2 °C–8 °C, in 4 ure, če je shranjeno pri 25 °C. Z mikrobiološkega stališča je treba zdravilo uporabiti takoj.
After dilution the solution for infusion must have a final concentration of 1 to 5 mg/ml dalbavancin
Po redčenju mora raztopina za infundiranje vsebovati končno koncentracijo 1 do 5 mg/ml dalbavancina.
After dilution to lower concentrations, immediate use is recommended.
Priporočamo, da zdravilo uporabite takoj po redčenju.
After dilution use within 24 hours.
Po razredčitvi uporabite v 24 urah.
After dilution use within 24 hours.
Po redčenju je zdravilo uporabno še 24 ur.
After dilution use within 24 hours.
Po redčenju zdravilo uporabite v 24 urah.
After dilution with 0.2 mL of sodium chloride 9 mg/mL (0.9%) solution for injection, 0.1 mL of the diluted solution contains 0.125 mg ocriplasmin.
Po redčenju z 0,2 ml raztopine 0,9-odstotnega natrijevega klorida (9 mg/ml) za injiciranje vsebuje 0,1 ml razredčene raztopine 0,125 mg okriplazmina.
After dilution, administer 1 dose of 0.2 ml of vaccine per chicken by subcutaneous injection in the neck.
Po razredčenju dajte en odmerek 0,2 ml cepiva na piščanca subkutano v vrat.
After dilution, and from a microbiological point of view, the product should be used immediately.
Z mikrobiološkega stališča je treba zdravilo uporabiti takoj po ustreznem redčenju.
After dilution, chemical and physical in-use stability has been demonstrated for 6 hours at 25˚C.
Dokazano je bilo, da je po redčenju raztopina kemično in fizikalno stabilna 6 ur pri temperaturi 25 ˚C.
After dilution, chemical and physical stability has been demonstrated for 30 hours up to 25ºC.
Po razredčitvi je kemična in fizikalna stabilnost dokazana za 30 ur pri temperaturi do 25 ºC.
After dilution, if not used immediately, storage times and conditions before use are the responsibility of your doctor and would normally not be longer than 24 hours at 2ºC – 8ºC, unless dilution has taken place in a sterile environment.
Če zdravilo ni porabljeno takoj po redčenju, je vaš zdravnik odgovoren za čas in pogoje shranjevanja pred uporabo in ti ne bi smeli trajati dlje kot 24 ur pri temperaturi med 2 in 8 °C, razen če se je redčenje opravilo v sterilnih pogojih.
After dilution, RoActemra for RA, sJIA and pJIA patients should be administered as an intravenous infusion over 1 hour.
Po razredčenju je treba zdravilo RoActemra bolnikom z revmatoidnim artritisom, sJIA in pJIA dati v 1-urni intravenski infuziji.
After dilution, the medicinal product should be used within 24 hours.
Po redčenju je treba zdravilo uporabiti v roku 24 ur.
After dilution, the product should be used immediately.
Razredčen izdelek je treba takoj uporabiti.
After dilution, the product should be used immediately.
Razredčen izdelek morate takoj uporabiti.
After dilution, use immediately
Uporabite takoj po razredčenju.
After dilution:
Po redčenju
After dilution: 1 ml of solution contains 0.5 mg of busulfan
Po redčenju: 1 ml raztopine vsebuje 0,5 mg busulfana.
After dilution: Chemical and physical in-use stability has been demonstrated for 24 hours at 2°C - 8°C and at 25°C after dilution in 100 ml 0.9% w/v sodium chloride solution or 100 ml 5% w/v glucose.
Po razredčenju: Kemična in fizikalna stabilnost sta med uporabo dokazani 24 ur pri temperaturi od 2°C - 8°C in pri temperaturi 25°C po razredčenju s 100 ml 0,9% m/v raztopine natrijevega klorida ali 100 ml 5% m/v glukoze.
After dilution: Chemical and physical in-use stability has been demonstrated for up to 24 hours at 2C – 8C followed by up to 24 hours at 23C – 27C.
Po razredčitvi: fizikalna in kemijska obstojnost za uporabo pripravljene raztopine je bila dokazana za obdobje 24 ur pri temperaturi od 2 °C–8 °C in nadalje za največ 24 ur pri temperaturi od 23 °C–27 °C.
After dilution: Chemical and physical in-use stability of the diluted solution for infusion has been demonstrated for 24 hours at 2 °C to 8 °C. From a microbiological point of view, the product should be used immediately.
Po redčenju: Dokazano je bilo, da je kemična in fizikalna stabilnost razredčene raztopine za infundiranje 24 ur pri temperaturi od 2 °C do 8 °C. Z mikrobiološkega stališča je treba zdravilo uporabiti takoj.
After dilution: Chemical and physical in-use stability of the diluted solution for infusion has been demonstrated for 24 hours at 2 °C to 8 °C. From a microbiological point of view, the product should be used immediately.
Po redčenju: razredčena raztopina za infundiranje ostane kemično in fizikalno stabilna še 24 ur pri temperaturi od 2 °C do 8 °C. Z mikrobiološkega vidika morate zdravilo porabiti takoj.
After dilution: Chemical and physical in-use stability of the diluted solution for infusion has been demonstrated for 24 hours at 2 °C to 8 °C. From a microbiological point of view, the product should be used immediately.
Po redčenju: razredčena raztopina za infundiranje ostane kemično in fizikalno stabilna še 24 ur pri temperaturi od 2°C do 8 °C. Z mikrobiološkega vidika morate zdravilo porabiti takoj.
After dilution: Chemical and physical in-use stability of the diluted solution for infusion has been demonstrated for 24 hours at 2°C to 8°C. From a microbiological point of view, the product should be used immediately.
Po razredčitvi: Kemična in fizikalna stabilnost razredčene raztopine za infundiranje med uporabo sta bili dokazani za obdobje 24 ur pri temperaturi od 2 °C do 8 °C. Z mikrobiološkega stališča je zdravilo treba uporabiti takoj.
After dilution: Chemical and physical in-use stability of the diluted solution for infusion has been demonstrated for 24 hours at 2°C to 8°C. From a microbiological point of view, the product should be used immediately.
Po razredčitvi: Kemična in fizikalna stabilnost razredčene raztopine za infundiranje sta bili dokazani za obdobje 24 ur pri temperaturi od 2 °C do 8 °C. Z mikrobiološkega stališča je zdravilo treba uporabiti takoj.
After dilution: From a microbiological point of view the product should be used immediately.
Po redčenju: Z mikrobiološkega vidika je treba zdravilo uporabiti takoj.
After dilution: From a microbiological point of view, the diluted solution for infusion should be used immediately.
Po redčenju: Z mikrobiološkega vidika je treba zdravilo uporabiti takoj.
After discontinuation of a strong CYP3A inhibitor, resume the ceritinib dose that was taken prior to initiating the strong CYP3A inhibitor.
Po ukinitvi močnega zaviralca CYP3A naj bolnik ponovno začne z jemanjem odmerka, ki ga je jemal pred uvedbo močnega zaviralca CYP3A.
After discontinuation of etanercept, symptoms of arthritis generally returned within a month.
Po prekinitvi zdravljenja z etanercepom so se simptomi artritisa največkrat ponovno pojavili že v enem mesecu.
After discontinuation of GANFORT, pigmentation of iris may be permanent.
Po prenehanju uporabe zdravila GANFORT lahko pigmentacija šarenice ostane trajna.
After discontinuation of IOA, return to ovulation in the first 28 days after last tablet intake was observed in 79 % of the women.
Po prekinitvi jemanja zdravila IOA so pri 79 % žensk opazili povrnitev ovulacije v prvih 28 dneh po zaužitju zadnje tablete.
After discontinuation of short-term and long-term treatment with pregabalin. withdrawal symptoms have been observed in some patients.
Po prekinitvi kratkotrajnega in dolgotrajnega zdravljenja s pregabalinom so pri nekaterih bolnikih opazili odtegnitvene simptome.
After discontinuation, the effect of Eperzan may continue as plasma levels of albiglutide decline slowly over about 3 to 4 weeks.
Po prenehanju uporabe lahko učinek zdravila Eperzan traja še približno 3 do 4 tedne, ker se koncentracija albiglutida v plazmi znižuje počasi.
After disease flare, children received Simponi 30 mg/m2 (maximum 50 mg) + MTX.
Po ponovnem zagonu bolezni so otroci prejeli 30 mg/m2 (največ 50 mg) zdravila Simponi in metotreksat.
After dissolving the lutropin alfa powder, draw the solution back into the syringe and re-inject it into the vial containing GONAL-f.
Po raztapljanju praška lutropina alfa izvlecite raztopino nazaj v injekcijsko brizgo in jo ponovno injicirajte v vialo s praškom zdravila GONAL-f.
After dissolving the lutropin alfa powder, draw the solution back into the syringe and re-inject it into the vial containing GONAL-f.
Po raztapljanju praška lutropina alfa, izvlecite raztopino nazaj v injekcijsko brizgo in jo ponovno injicirajte v vialo s praškom zdravila GONAL-f.
After dissolving, a deliverable amount of
Po pripravi vsebuje uporabna količina
After dose reduction, interrupt treatment, if
prekinitev zdravljenja po znižanju odmerka , če:
After dose reduction, interrupt treatment, if
prekinitev zdravljenja po znižanju odmerka, če:
After doses of 0.5 mg/kg (~40 mg), clearances ranged from 11 to 15 ml/hour, the distribution volume (Vss) ranged from 5 to 6 litres and the mean terminal phase half- life was approximately two weeks.
Po odmerkih 0,5 mg/kg (~40 mg) je bil očistek od 11 do 15 ml/uro, volumen distribucije (Vss) od 5 do 6 litrov in povprečni razpolovni čas terminalne faze približno dva tedna.
After each dose of Norvir, separate the plunger and the syringe.
Po vsakem odmerku zdravila Norvir ločite bat in brizgo.
After each infusion, the patient should be observed for 2 hours for infusion associated reactions.
Po infundiranju zdravila je treba bolnika še dve uri opazovati zaradi z infuzijo povezanih reakcij.
After each inhalation of Colobreathe, the mouth should be rinsed with water.
Po vsakem vdihavanju zdravila Colobreathe je treba usta izprati z vodo.
After each injection of Xiapex, your penis may be wrapped with a bandage.
Po vsaki injekciji zdravila Xiapex bodo morda vaš penis povili s povojem.
After each injection, patients should be observed in a health care facility by appropriately qualified personnel for at least 3 hours for signs and symptoms consistent with olanzapine overdose.
Po vsakem injiciranju mora ustrezno usposobljeno osebje v zdravstvenih ustanovah najmanj 3 ure opazovati bolnike za znake in simptome, značilne za preveliko odmerjanje olanzapina.
After eight weeks of treatment, the average amount of phosphate in the blood was reduced by about a fifth, from 2.0 mmol/l to 1.6 mmol/l.
Po osmih tednih zdravljenja se je povprečna raven fosfata v krvi znižala za približno petino, in sicer z 2,0 mmol/l na 1,6 mmol/l.
After either oral or intravenous administration of 14C irbesartan, about 20% of the radioactivity is recovered in the urine, and the remainder in the faeces.
Po peroralni ali intravenski uporabi irbesartana 14C se s sečem izloči približno 20 % radioaktivne snovi, preostanek pa z blatom.
After either oral or intravenous administration, sildenafil is excreted as metabolites predominantly in the faeces (approximately 80 % of administered oral dose) and to a lesser extent in the urine (approximately 13 % of administered oral dose).
Sildenafil se po peroralni in intravenski uporabi izloča v obliki presnovkov, pretežno z blatom (približno 80 % peroralnega odmerka) in v manjši meri z urinom (približno 13 % peroralnega odmerka).
After either oral or intravenous administration, sildenafil is excreted as metabolites predominantly in the faeces (approximately 80 % of administered oral dose) and to a lesser extent in the urine (approximately 13 % of administered oral dose).
Sildenafil se po peroralni in intravenski uporabi izloči v obliki presnovkov, pretežno v blatu (približno 80 % peroralnega odmerka) in v manjši meri v urinu (približno 13 % peroralnega odmerka).
After either oral or intravenous administration, sildenafil is excreted as metabolites predominantly in the faeces (approximately 80% of administered oral dose) and to a lesser extent in the urine (approximately 13% of administered oral dose).
Sildenafil se po peroralni in intravenski uporabi izloča v obliki presnovkov, pretežno z blatom (približno 80 % peroralnega odmerka) in v manjši meri s sečem (približno 13 % peroralnega odmerka).
After either oral or intravenous administration, sildenafil is excreted as metabolites predominantly in the faeces (approximately 80% of administered oral dose) and to a lesser extent in the urine (approximately 13% of administered oral dose).
Sildenafil se po peroralni in intravenski uporabi izloča v obliki presnovkov, pretežno z blatom (približno 80 % peroralnega odmerka) in v manjši meri z urinom (približno 13 % peroralnega odmerka).
After either oral or intravenous administration, sildenafil is excreted as metabolites predominantly in the faeces (approximately 80% of administered oral dose) and to a lesser extent in the urine (approximately 13% of administered oral dose).
Sildenafil se po peroralni in intravenski uporabi izloči v obliki presnovkov, pretežno v blatu (približno 80% peroralnega odmerka) in v manjši meri v urinu (približno 13% peroralnega odmerka).
After either oral or IV administration of 14C irbesartan, about 20 % of the radioactivity is recovered in the urine, and the remainder in the faeces.
Po peroralnem ali i.v. dajanju 14C irbesartana, se približno 20 % radioaktivnosti izloči z urinom in preostanek z blatom.
After either oral or IV administration of 14C irbesartan, about 20% of the radioactivity is recovered in the urine, and the remainder in the faeces.
Po peroralnem ali i.v. dajanju 14C irbesartana, se približno 20% radioaktivnosti izloči z urinom in preostanek z blatom.
After either oral or IV administration of 14C irbesartan, about 20% of the radioactivity is recovered in the urine, and the remainder in the faeces.
Po peroralnem ali intravenskem dajanju 14C irbesartana se približno 20 % radioaktivnosti izloči s sečem, preostanek pa z blatom.
After ellaOne intake menstrual periods can sometimes occur a few days earlier or later than expected.
Po zaužitju zdravila ellaOne lahko menstruacija včasih nastopi nekaj dni prej ali pozneje od predvidenega datuma.
After excluding patients in whom exposure to study drug was less than one year at the time of diagnosis of bladder cancer, there were 7 cases (0.06%) on pioglitazone and 2 cases (0.02%) in control groups.
Ko so izločili bolnike, ki so bili va času diagnoze rak mehurja preiskovanemu zdravilu izpostavljeni manj kot eno leto, so ugotovili 7 primerov (0,06 %) raka mehurja pri pioglitazonu in 2 primera (0,02 %) v kontrolnih skupinah.